Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem
- Klíčová slova
- DOSING INSTRUCTIONS, DOSING INTERVAL, MEDICATION ADHERENCE, NECESSITY-CONCERNS FRAMEWORK, ORAL BISPHOSPHONATES, OSTEOPOROSIS,
- MeSH
- adherence k farmakoterapii psychologie MeSH
- aplikace orální MeSH
- bisfosfonáty aplikace a dávkování terapeutické užití MeSH
- hodnocení adherence k farmakoterapii * MeSH
- inhibitory kostní resorpce aplikace a dávkování terapeutické užití MeSH
- kyselina ibandronová MeSH
- lidé středního věku MeSH
- lidé MeSH
- postmenopauzální osteoporóza farmakoterapie psychologie MeSH
- průřezové studie MeSH
- průzkumy a dotazníky MeSH
- průzkumy zdravotní péče MeSH
- rozvrh dávkování léků MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- zdraví - znalosti, postoje, praxe * MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
- Názvy látek
- bisfosfonáty MeSH
- inhibitory kostní resorpce MeSH
- kyselina ibandronová MeSH
OBJECTIVES: Low adherence to treatment with bisphosphonates significantly impedes its effectiveness. The objectives were: (1) to compare adherence to oral weekly and monthly bisphosphonates with emphasis on dosing instructions; and (2) to study associations between adherence and beliefs about the bisphosphonate treatment among women ≥ 55 years. METHODS: A multicenter survey was performed in secondary-care patients with osteoporosis. Osteoporosis Specific Morisky Medication Adherence Scale (OS-MMAS), questions on compliance with five dosing instructions and Beliefs about Medicines Questionnaire (BMQ) Specific were used. RESULTS: As many as 363 questionnaires (response rate 95%) were analyzed. Respondents (mean age 69 years) were treated with weekly bisphosphonates (37%) or monthly ibandronate (63%). Based on OS-MMAS, 67% of respondents showed high adherence with no differences between the subgroups. Only 44% of respondents were compliant with all dosing instructions. Compliance with dosing instructions concerning time interval (fasting and staying upright) was 71% in weekly and 52% in monthly subgroups, respectively (p < 0.001). Compliance with dosing instructions correlated positively with education (p = 0.009). The mean BMQ necessity score of 18.4 was greater than the mean BMQ concerns score of 13.3. OS-MMAS score correlated with necessity (p = 0.010). Persistence derived from OS-MMAS correlated with both necessity (p = 0.014) and concerns (p = 0.041). CONCLUSION: Despite relatively high adherence to the treatment, most patients do not follow dosing instructions. Reduced bioavailability, particularly of monthly ibandronate, can be expected in clinical practice. Adherence-related outcomes are associated with beliefs about the oral treatment with bisphosphonates.
Citace poskytuje Crossref.org
